Boule Diagnostics AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
February 02, 2023 at 01:30 am EST
Share
Boule Diagnostics AB (publ) reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported sales was SEK 149.2 million compared to SEK 140.3 million a year ago. Net income was SEK 2.9 million compared to SEK 17.3 million a year ago. Basic earnings per share from continuing operations was SEK 0.09. Diluted earnings per share from continuing operations was SEK 0.09.
For the full year, sales was SEK 548.1 million compared to SEK 463.3 million a year ago. Net income was SEK 12.7 million compared to SEK 23.3 million a year ago. Basic earnings per share from continuing operations was SEK 0.46. Diluted earnings per share from continuing operations was SEK 0.45.
Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Companyâs product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Companyâs primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.
BOULE DIAGNOSTICS AB 
